Skip to main content

13 Result(s)

within Senji Kasahara Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

    We previously conducted a randomized phase II trial of OCV-501, a WT1 peptide presented by helper T cells, in elderly AML (acute myeloid leukemia) patients in first remission, indicating no difference in 2-yea...

    Tomoki Naoe, Akiko Saito, Nahoko Hosono, Senji Kasahara… in Cancer Immunology, Immunotherapy (2023)

    Download PDF (669 KB) View Article

  2. Article

    Open Access

    A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

    This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (...

    Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa… in Experimental Hematology & Oncology (2022)

    Download PDF (636 KB) View Article

  3. Article

    Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin… in Nature Medicine (2021)

    Download PDF (526 KB) View Article

  4. Article

    Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    A Correction to this paper has been published: https://doi.org/10.1038/s41591-021-01253-5.

    Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin… in Nature Medicine (2021)

    Download PDF (533 KB) View Article

  5. No Access

    Article

    Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute ...

    Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin… in Nature Medicine (2020)

  6. No Access

    Article

    Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2

    The aim of this study was to assess the effects of acyclic retinoid (ACR) and vitamin K2 (VK2) in HL-60 cells.

    Junichi Kitagawa, Takeshi Hara… in Journal of Cancer Research and Clinical On… (2011)

  7. No Access

    Article

    Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

    We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2010)

  8. No Access

    Article

    Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

    We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). H...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2009)

  9. No Access

    Article

    Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

    The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

    Jun-ichi Kitagawa, Takeshi Hara… in Journal of Cancer Research and Clinical On… (2009)

  10. No Access

    Article

    Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide

    To evaluate the efficacy and safety of a novel low dose chemotherapy as a remission induction regimen for elderly de novo AML patients ineligible for intensive chemotherapy.

    Hisashi Tsurumi, Nobuhiro Kanemura… in Journal of Cancer Research and Clinical On… (2007)

  11. No Access

    Article

    Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

    The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).

    Hideko Goto, Hisashi Tsurumi, Masao Takemura… in Journal of Cancer Research and Clinical On… (2005)

  12. No Access

    Article

    Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma

    To compare the efficacy and safety of a biweekly CHOP regimen consisting of cyclophosphamide (CPA), doxorubicin (DOX), vincristine (VCR), and prednisolone (PSL) and those of a biweekly THP-COP regimen contain...

    Hisashi Tsurumi, Toshiki Yamada… in Journal of Cancer Research and Clinical On… (2004)

  13. No Access

    Article

    Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A

    We investigated whether immunosuppressive therapy using methylprednisolone (mPSL) with or without cyclosporin A (CsA) could benefit patients with myelodysplastic syndrome (MDS). Eligibility criteria for this s...

    Toshiki Yamada, Hisashi Tsurumi… in Journal of Cancer Research and Clinical On… (2003)